Literature DB >> 6608985

Lymphocyte response to pokeweed mitogen in chronic lymphocytic leukemia.

H V Lamberson, F R Davey, C M Schreck, K Zamkoff, A S Kurec.   

Abstract

The response of lymphocyte subpopulations to pokeweed mitogen (PWM) was studied in normal volunteers and patients with B-cell chronic lymphocytic leukemia (CLL). Since unfractionated peripheral blood mononuclear (PBM) cells from CLL patients consist of a markedly increased proportion of B-lymphocytes and a decreased proportion of T-lymphocytes, enriched fractions of CLL B-cells and CLL T-cells were cultured in 1:1 proportions in autologous and allogeneic combinations with normal B-cell and T-cell-enriched fractions. Cultures containing normal B-cells with either autologous or allogeneic normal T-cells responded well to PWM. CLL T-cells were capable of providing a helper function for both proliferation and differentiation of normal B-cells, which was not significantly different from that provided by allogeneic normal T-cells. CLL B-lymphocytes were unresponsive to PWM when cultured in the presence of either autologous CLL T-lymphocytes or allogeneic normal T-lymphocytes. The responsiveness of CLL B-cells was not restored by the addition of normal peripheral blood monocytes to the cultures. These experiments indicate that there is an intrinsic B-cell defect which prevents CLL B-lymphocytes from responding to PWM.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608985     DOI: 10.1002/1097-0142(19840601)53:11<2481::aid-cncr2820531120>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Impaired mitogen responses of the non-leukaemic B cells from patients with chronic lymphocytic leukaemia.

Authors:  A Morgan; J Eaves; J W Mockford; V Malkovska
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

2.  Immuno-phenotype and proliferative response of B-cell chronic lymphocytic leukemia.

Authors:  S Karfa; R Gopal; J S Nadkarni
Journal:  Med Oncol Tumor Pharmacother       Date:  1990
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.